loading
Precedente Chiudi:
$69.36
Aprire:
$68
Volume 24 ore:
134.53K
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.41B
Reddito:
$486.82M
Utile/perdita netta:
$18.78M
Rapporto P/E:
82.36
EPS:
0.82
Flusso di cassa netto:
$100.45M
1 W Prestazione:
-0.89%
1M Prestazione:
+15.89%
6M Prestazione:
+19.30%
1 anno Prestazione:
+0.76%
Intervallo 1D:
Value
$66.38
$68.28
Intervallo di 1 settimana:
Value
$65.28
$69.45
Portata 52W:
Value
$52.50
$70.00

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name
Nome
Ani Pharmaceuticals Inc
Name
Telefono
(218) 634-3500
Name
Indirizzo
210 MAIN STREET WEST, BAUDETTE, MN
Name
Dipendente
642
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-08
Name
Ultimi documenti SEC
Name
ANIP's Discussions on Twitter

Confronta ANIP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ANIP
Ani Pharmaceuticals Inc
67.69 1.41B 486.82M 18.78M 100.45M 0.82
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
161.29 73.88B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.14 48.17B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.47 47.59B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.09 17.28B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
308.94 13.78B 2.76B 1.11B 898.10M 22.77

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-14 Iniziato Jefferies Buy
2025-03-12 Iniziato JP Morgan Overweight
2024-12-11 Iniziato Leerink Partners Outperform
2024-10-11 Iniziato Piper Sandler Overweight
2024-03-15 Iniziato CapitalOne Overweight
2023-08-22 Reiterato H.C. Wainwright Buy
2023-03-01 Iniziato Guggenheim Buy
2022-09-07 Iniziato H.C. Wainwright Buy
2021-11-02 Iniziato Truist Buy
2020-05-07 Downgrade Cantor Fitzgerald Overweight → Neutral
2019-09-12 Iniziato Guggenheim Buy
2019-05-10 Downgrade Raymond James Strong Buy → Outperform
2017-10-16 Reiterato Canaccord Genuity Buy
2017-07-31 Iniziato Canaccord Genuity Buy
2017-02-22 Downgrade ROTH Capital Buy → Neutral
2016-06-23 Iniziato Raymond James Strong Buy
2016-05-24 Downgrade Standpoint Research Buy → Hold
2015-11-13 Iniziato Standpoint Research Buy
2015-09-28 Aggiornamento ROTH Capital Neutral → Buy
2015-08-05 Reiterato Oppenheimer Outperform
2015-08-04 Reiterato ROTH Capital Neutral
2015-07-31 Reiterato Oppenheimer Outperform
2015-07-15 Reiterato ROTH Capital Neutral
2015-06-23 Reiterato Oppenheimer Outperform
2015-05-18 Reiterato ROTH Capital Neutral
2015-05-06 Reiterato Oppenheimer Outperform
2015-04-10 Downgrade ROTH Capital Buy → Neutral
2015-02-26 Reiterato ROTH Capital Buy
2015-02-18 Reiterato Oppenheimer Outperform
Mostra tutto

Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie

pulisher
09:02 AM

ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com UK

09:02 AM
pulisher
08:42 AM

Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - TradingView

08:42 AM
pulisher
06:48 AM

ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq

06:48 AM
pulisher
Apr 02, 2025

Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - TradingView

Apr 02, 2025
pulisher
Mar 31, 2025

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire

Mar 31, 2025
pulisher
Mar 28, 2025

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st

Mar 28, 2025
pulisher
Mar 25, 2025

5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView

Mar 25, 2025
pulisher
Mar 24, 2025

Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research

Mar 24, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire

Mar 18, 2025
pulisher
Mar 14, 2025

Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

ANI Pharma rises on expanded US approval for eye-disease drug - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

ANI Pharmaceuticals Says FDA Approves Expanded Label for Iluvien -March 14, 2025 at 07:23 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire

Mar 14, 2025
pulisher
Mar 14, 2025

ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan

Mar 14, 2025
pulisher
Mar 14, 2025

JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

ANI Pharma stock wins J.P. Morgan bullish view (ANIP:NASDAQ) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Exploring Growth Opportunities: Raytheon, ANI Pharmaceuticals, DeckersNews and Statistics - IndexBox, Inc.

Mar 12, 2025
pulisher
Mar 12, 2025

Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

JPMorgan Initiates ANI Pharmaceuticals at Overweight With $85 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

ANI Pharmaceuticals at Leerink Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

ANI Pharmaceuticals Discusses Alimera Acquisition Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Ani Pharmaceuticals’ chief HR officer Krista Davis sells $60,860 in stock - Investing.com Canada

Mar 11, 2025
pulisher
Mar 09, 2025

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St

Mar 09, 2025
pulisher
Mar 07, 2025

Top Executive at ANI Pharmaceuticals Sells Thousands in Stock! - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Ani Pharmaceuticals SVP sells $323,049 in stock By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

ANI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat

Mar 07, 2025

Ani Pharmaceuticals Inc Azioni (ANIP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$9.95
price down icon 7.85%
$32.55
price up icon 0.31%
$95.31
price down icon 2.00%
$8.525
price down icon 0.93%
$105.98
price down icon 1.57%
$300.42
price down icon 4.61%
Capitalizzazione:     |  Volume (24 ore):